You are here

hemophilia

Sanofi revises fitusiran dosing to cut risk of thrombotic events in hemophilia phase 3

Sanofi revises fitusiran dosing to cut risk of thrombotic events in hemophilia phase 3

Fierce Biotech

Flag link:

Gene therapy for hemophilia: So close, yet so far away

Gene therapy for hemophilia: So close, yet so far away

BioPharma Dive

Flag link:

Novo invests in Hemab, a company going against the hemophilia gene therapy grain with a plan for bispecifics

Novo invests in Hemab, a company going against the hemophilia gene therapy grain with a plan for bispecifics

Endpoints

Flag link:

Sanofi accepts a lengthy delay as its hemophilia drug fitusiran resumes a PhIII after safety fears forced a halt

Sanofi accepts a lengthy delay as its hemophilia drug fitusiran resumes a PhIII after safety fears forced a halt

Endpoints

Flag link:

Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy

Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy

Pharmaceutical Business Review

clinical trials

Flag link:

Sanofi/Alnylam’s haemophilia drug hits another safety speed-bump

Sanofi/Alnylam’s haemophilia drug hits another safety speed-bump

Pharmaforum

Flag link:

Sharp knives and hemophilia? No problem in Roche's new work-life miniseries

Sharp knives and hemophilia? No problem in Roche's new work-life miniseries

Fierce Pharma

pharma marketing

Flag link:

Sanofi's hemophilia drug comes into focus as delays hit a key competitor

Sanofi's hemophilia drug comes into focus as delays hit a key competitor

BioPharma Dive

Flag link:

Novo gets PhIII hemophilia trials for a Roche rival back on track after completing work-around on blood clot threat

Novo gets PhIII hemophilia trials for a Roche rival back on track after completing work-around on blood clot threat

Endpoints

clinical trials

Flag link:

Sangamo R&D chief hits the exit as it splits R&D into separate units

Sangamo R&D chief hits the exit as it splits R&D into separate units

Fierce Biotech

Flag link:

Sigilon picks up $80M to test hemophilia cell therapy in humans

Sigilon picks up $80M to test hemophilia cell therapy in humans

Fierce Biotech

Siglion Therapeutics

Flag link:

Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy

Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy

Xconomy

clinical trials

Flag link:

BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy

BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy

Motley Fool

Flag link:

BioMarin sets gene therapy sights beyond hemophilia

BioMarin sets gene therapy sights beyond hemophilia

BioPharma Dive

Flag link:

Value-based pricing for gene therapy? Maybe not ready for hemophilia

Value-based pricing for gene therapy? Maybe not ready for hemophilia

Biopharma Dive

valoctocogene roxaparvovec

Flag link:

Sangamo keeps pressure on rivals with updated hemophilia data

Sangamo keeps pressure on rivals with updated hemophilia data

Biopharma Dive

Flag link:

Why Novo Nordisk should buy Uniqure

Why Novo Nordisk should buy Uniqure

EP Vantage

Flag link:

The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?

The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?

Stat

Tremeau Pharmaceuticals

hemophilic arthropathy

Flag link:

Novo taps bluebird bio for gene-editing tech

Novo taps bluebird bio for gene-editing tech

Fierce Biotech

Flag link:

BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

Fierce Biotech

valoctocogene roxaparvovec

Flag link:

Pages